论文部分内容阅读
报告58例慢润性膀胱癌.其中52例采用膀胱部分切除手术方法,3例行膀胱部分切除并患侧输尿管膀胱再吻合,3倒行患侧肾、输尿管、膀胱部分切除.手术后膀胱内科灌注卡介苗(BCG免疫治疗)或噎替哌(ThiotePa)、丝裂素(MMC)化疗.随访结果:复发 7例(12％),木后 2～4年死亡 3例(5.2％),余 55例(94.8％)均存活至今.认为对浸润性膀胱癌施行膀胱部分切除、术后采用免疫疗法与化疗综合治疗,不仅能有效地保留膀胱,使其维持自身的生理功能,而且能成功地进行抗肿瘤免疫治疗与化疗,降低复发率、提高生存率.
Fifty-eight patients with chronic-cancerous bladder cancer were reported, including 52 cases undergone partial resection of the bladder, 3 cases underwent resection of the bladder and anastomosis of the affected ureter and bladder, 3 cases of rejection of the affected side, the ureter and partial removal of the bladder. (BCG immunotherapy) or Thiotepa and mitomycin (MMC) chemotherapy.Results: 7 cases (12%) were relapsed, 3 cases (5.2%) died after 2 ~ 4 years and 55% (94.8%) survived to the present.It is considered that partial bladder resection for invasive bladder cancer and postoperative immunotherapy combined with chemotherapy can not only effectively retain the bladder and maintain its physiological function, but also succeed Anti-tumor immunotherapy and chemotherapy, reduce the recurrence rate and improve the survival rate.